NNC0165-1875 combination with semaglutide investigated for enhanced obesity treatment

The global prevalence of obesity continues to rise, posing significant health challenges including increased risk of type 2 diabetes, cardiovascular disease, and certain cancers. While GLP-1 receptor agonists like semaglutide have revolutionized weight management by targeting GLP-1R to reduce appetite and improve satiety, a substantial need remains for therapies that offer greater weight loss or improved patient response. Exploring novel compounds like NNC0165-1875 in combination with established treatments aims to identify synergistic pathways for more effective and sustained weight reduction.

This randomized, placebo-controlled clinical study is investigating the efficacy and safety of NNC0165-1875 in combination with semaglutide in individuals with obesity. Participants are randomly assigned to receive either semaglutide plus NNC0165-1875 or semaglutide plus a placebo. The intervention involves two injections per week, administered via a pre-filled pen under the skin. The study duration is approximately 26 weeks, with participants attending 17 clinic visits. Four of these visits require an 8-hour fasting period (water allowed until 2 hours prior) to facilitate specific metabolic assessments.

This research study is currently in progress, and as such, specific findings regarding the efficacy or safety of NNC0165-1875 in combination with semaglutide are not yet available. The study's primary objective is to investigate how well this novel combination therapy works in people with obesity, and to understand its effects on the body. Results will be published upon completion of the trial.